Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy
Table 1
Baseline characteristics of the patients with decompensated liver cirrhosis.
Patients with HCC (n = 41)
Patients without HCC (n = 88)
value
Age, years
61 (53.5–66)
51 (44.25–58.75)
≤0.001
Age <50/age ≥50
7/34
42/46
≤0.001
Male/female
30/11
48/40
0.04
Complications, n (%)
Encephalopathy
6 (14.6)
8 (9.1)
0.35
GI bleeding
1 (2.4)
8 (9.1)
0.27
Ascites
21 (51.2)
45 (51.1)
0.94
Splenectomy (n = 17)
5 (12.2)
12 (13.6)
0.82
Family history of CHB (Y/N)
15/26
45/43
0.40
Previous antiviral therapy
—
Nucleosides, n (%)
25 (61.0)
47 (53.4)
0.29
Nucleotides, n (%)
8 (19.5)
13 (14.8)
Combination therapy, n (%)
5 (12.2)
10 (11.3)
Sequential therapy, n (%)
3 (7.3)
18 (20.5)
Laboratory findings
HBeAg positive, n (%)
13 (31.7)
19 (21.6)
0.22
HBV DNA (log IU/mL)
4.17 ± 1.40
4.01 ± 1.64
0.59
HBV DNA positive at 6th month, n (%)
7 (17.0)
12 (13.6)
0.60
ALT (U/L)
57.29 ± 55.89
52.97 ± 47.14
0.68
Total bilirubin (μmol/L)
35.21 ± 18.43
35.53 ± 28.95
0.95
Cholinesterase (U/L)
4245.95 ± 1946.29
3653.83 ± 1655.46
0.12
Platelet counts (E + 09/L)
71.96 ± 49.01
81.97 ± 67.06
0.40
INR
1.30 ± 0.21
1.31 ± 0.33
0.82
Sodium (mmol/L)
140.83 ± 3.20
140.45 ± 2.5
0.49
Creatinine (μmol/L)
76.50 ± 17.00
75.77 ± 19.36
0.84
AFP (ng/ml)
3.28 (1.71–4.21)
4.85 (2.36–19.70)
0.14
MELD
11.63 ± 3.54
11.25 ± 4.56
0.64
Data are shown as means ± standard deviation or median (IQR). Abbreviations: HCC, hepatocellular carcinoma; GI, gastrointestinal; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid; ALT, alanine aminotransferase; INR, prothrombin time/international normalized ratio; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease.
